Cardiff Oncology Inc (CRDF) Stock Price, Quote & News

Company Profile

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated ongoing or planned trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, and triple negative breast cancer...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 952 7570

Website: www.cardiffoncology.com

Address:

11055 Flintkote Avenue, San Diego, United States

biohuntress Aug. 4 at 10:21 PM

$CRDF hanging in there .... Nicholas Choong, MD Pfizer

1 · Reply

Huber65 Aug. 4 at 9:44 PM

$CRDF directors are normally aware of buyouts

1 · Reply

NSVEE Aug. 4 at 9:31 PM

$CRDF a director would (generally) not be aware of an acquisition in process. an officer likely would. it’s good news if you’re not seeing officer insider buys. They can’t make trades if there‘s an acquisition in progress. if they make a trade, then you know theres likely no acquisition incoming. tldr: it’s a good thing theres only a director level buying shares.

0 · Reply

shezam Aug. 4 at 9:19 PM

$CRDF A reminder that when retail traders/investors have low sentiment and start to throw in the towels, whales start scooping.

0 · Reply

Get_Out Aug. 4 at 8:45 PM

$CRDF fuck this shit. dead fucking money. tech is flying and have had my money tied up in this shit for 5 fucking years sitting on a loss.

2 · Reply

spartaksus Aug. 4 at 8:16 PM

$CRDF CRDF Board - fire Erlander ASAP. Are you blind not to see he is clearly unfit for his position? How long will you ignore and tolerate his mistakes and mismanagement? Slow progress costs other people´s lives.

1 · Reply

BullRun4 Aug. 4 at 8:02 PM

$CRDF I am still bullish going into Tuesday. Staying positive because the data was good and by December we will have additional PFS and DoR data

1 · Reply

IRockIce Aug. 4 at 6:50 PM

$CRDF closing green would be

0 · Reply

smolcapcat Aug. 4 at 6:20 PM

$CRDF shrekt all the call options

1 · Reply

Get_Out Aug. 4 at 6:13 PM

$CRDF insider buys means no buyout imminent

1 · Reply

Why Is Cardiff Oncology Stock Trading Lower After Colorectal Cancer Data?

Jul 30, 2025, 11:32 AM EDT - 5 days ago

Cardiff Oncology: Data Update Resolves Some Signals

Jul 29, 2025, 4:07 PM EDT - 6 days ago

Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004)

Jun 27, 2025, 8:30 AM EDT - 5 weeks ago

Cardiff Oncology: Delayed Trial Data Update Unnerves Investors But Gives Bulls A Final Buy Low Opportunity

Jun 17, 2025, 4:39 PM EDT - 6 weeks ago

Cardiff Oncology Names Roger Sidhu as Medical Chief

Jun 17, 2025, 4:05 PM EDT - 6 weeks ago

Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC

Jun 2, 2025, 4:05 PM EDT - 2 months ago

Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025

May 14, 2025, 9:05 AM EDT - 2 months ago

Cardiff Oncology: Buying The First-Line Onvansertib Strategy

May 8, 2025, 4:05 PM EDT - 3 months ago

Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update

May 2, 2025, 3:35 AM EDT - 3 months ago

Cardiff Oncology: Expecting Massive Updates In Colon Cancer Soon

Apr 23, 2025, 4:05 PM EDT - 3 months ago

Cardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve Patients

Apr 15, 2025, 4:10 PM EDT - 3 months ago

Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Apr 15, 2025, 4:05 PM EDT - 3 months ago

Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer

Feb 27, 2025, 9:10 PM EST - 5 months ago

Cardiff Oncology, Inc. (CRDF) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 4:05 PM EST - 5 months ago

Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

Feb 24, 2025, 4:05 PM EST - 5 months ago

Cardiff Oncology to Present at Upcoming Investor Conferences

Feb 20, 2025, 4:05 PM EST - 5 months ago

Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update

Feb 18, 2025, 9:19 AM EST - 5 months ago

Cardiff Oncology: Pioneering RAS-Mutated Cancer Therapies With Onvansertib

Dec 14, 2024, 9:00 AM EST - 8 months ago

Undercovered Dozen: Ubiquiti, Ready Capital, Cardiff Oncology, Vodafone +

UI VOD DE ESPR FLNC GASS HII

Dec 12, 2024, 5:38 AM EST - 8 months ago

Cardiff Oncology: The Long-Awaited First-Line MCRC Data Are Here, But The Work Is Just Beginning

Dec 10, 2024, 5:05 PM EST - 8 months ago

Cardiff Oncology: Beats Standard Of Care In First Line Metastatic Colorectal Cancer

Dec 10, 2024, 7:20 AM EST - 8 months ago

Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering

Dec 10, 2024, 6:00 AM EST - 8 months ago

Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial

Oct 30, 2024, 4:30 PM EDT - 9 months ago

Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC

Oct 4, 2024, 1:10 PM EDT - 10 months ago

Cardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC Market

Aug 12, 2024, 2:57 PM EDT - 1 year ago

Cardiff: Second Half Of 2024 mCRC Data Is Major Inflection Point

Aug 10, 2024, 11:18 AM EDT - 1 year ago

Cardiff Oncology, Inc. (CRDF) Q2 2024 Earnings Call Transcript

May 29, 2024, 4:05 PM EDT - 1 year ago

Cardiff Oncology to Present at the Jefferies Healthcare Conference

May 21, 2024, 11:22 PM EDT - 1 year ago

Cardiff Oncology's Onvansertib: A Speculative Buy With Promising Data

May 13, 2024, 4:05 PM EDT - 1 year ago

Cardiff Oncology to Present at Upcoming Investor Conferences in May

May 3, 2024, 1:30 AM EDT - 1 year ago

Cardiff Oncology, Inc. (CRDF) Q1 2023 Earnings Call Transcript

May 2, 2024, 4:05 PM EDT - 1 year ago

Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update

Apr 25, 2024, 4:05 PM EDT - 1 year ago

Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update

Apr 8, 2024, 4:05 PM EDT - 1 year ago

Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study

Mar 8, 2024, 7:37 PM EST - 1 year ago

Cardiff Oncology: Why The Bulls Are Winning Right Now (Rating Upgrade)

Mar 6, 2024, 4:05 PM EST - 1 year ago

Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024

Feb 29, 2024, 8:06 PM EST - 1 year ago

Cardiff Oncology, Inc. (CRDF) Q4 2023 Earnings Call Transcript

Feb 29, 2024, 4:07 PM EST - 1 year ago

Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update

Feb 29, 2024, 4:06 PM EST - 1 year ago

Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC

Feb 29, 2024, 4:05 PM EST - 1 year ago

Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)

Feb 26, 2024, 8:00 AM EST - 1 year ago

Cardiff Oncology to Present at the Cowen 44th Annual Health Care Conference

Feb 22, 2024, 8:00 AM EST - 1 year ago

Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business Update

Jan 17, 2024, 10:30 AM EST - 1 year ago

Cardiff Oncology Announces Publication of Data from Phase 1b study in second-line KRAS-mutated mCRC in Clinical Cancer Research

Nov 20, 2023, 4:05 PM EST - 1 year ago

Cardiff Oncology to Present at the 35th Annual Piper Sandler Healthcare Conference

Nov 2, 2023, 9:11 PM EDT - 1 year ago

Cardiff Oncology, Inc. (CRDF) Q3 2023 Earnings Call Transcript

Nov 2, 2023, 4:05 PM EDT - 1 year ago

Cardiff Oncology Reports Third Quarter 2023 Results and Provides Business Update

Oct 26, 2023, 4:05 PM EDT - 1 year ago

Cardiff Oncology to Report Third Quarter 2023 Financial Results and Provide Business Update

Sep 27, 2023, 5:56 AM EDT - 2 years ago

Costco share fall following results, while Cardiff Oncology and MillerKnoll shares soar, and more moving stocks

COST MLKN PRGS TRUE

Sep 26, 2023, 4:05 PM EDT - 2 years ago

Cardiff Oncology Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer, including Single-Agent Activity from Onvansertib Monotherapy

Sep 5, 2023, 8:00 AM EDT - 2 years ago

Cardiff Oncology to Present at Upcoming Investor Conferences in September

biohuntress Aug. 4 at 10:21 PM

$CRDF hanging in there .... Nicholas Choong, MD Pfizer

1 · Reply

Huber65 Aug. 4 at 9:44 PM

$CRDF directors are normally aware of buyouts

1 · Reply

NSVEE Aug. 4 at 9:31 PM

0 · Reply

shezam Aug. 4 at 9:19 PM

$CRDF A reminder that when retail traders/investors have low sentiment and start to throw in the towels, whales start scooping.

0 · Reply

Get_Out Aug. 4 at 8:45 PM

$CRDF fuck this shit. dead fucking money. tech is flying and have had my money tied up in this shit for 5 fucking years sitting on a loss.

2 · Reply

spartaksus Aug. 4 at 8:16 PM

1 · Reply

BullRun4 Aug. 4 at 8:02 PM

$CRDF I am still bullish going into Tuesday. Staying positive because the data was good and by December we will have additional PFS and DoR data

1 · Reply

IRockIce Aug. 4 at 6:50 PM

$CRDF closing green would be

0 · Reply

smolcapcat Aug. 4 at 6:20 PM

$CRDF shrekt all the call options

1 · Reply

Get_Out Aug. 4 at 6:13 PM

$CRDF insider buys means no buyout imminent

1 · Reply

jacobmoney123 Aug. 4 at 5:05 PM

$CRDF I am expecting a buyout from Pfizer

1 · Reply

Mdmsi1 Aug. 4 at 4:59 PM

$CRDF 🔍 Regulatory Takeaways Cardiff’s ORR (49%) meets or exceeds prior accelerated approval standards in mCRC. Advantages: broad population, strong dose signal, chemo backbone integration. Challenges: control arm performance, statistical interpretation, funding CRDF‑005. 🧠 Strategic Considerations If CRDF‑005 replicates 49% ORR and shows >6-month DoR, accelerated approval is very likely. If median PFS/OS outperform SOC, full approval may follow quickly. Risks: data interpretation, duration signal, financing CRDF‑005 launch.

0 · Reply

Mdmsi1 Aug. 4 at 4:58 PM

1 · Reply

look2theblue Aug. 4 at 4:39 PM

$CRDF So long as insiders continue to buy shares we're good. They know more than all of retail, institutions, shorts, and hedgies combined. When they stop buying shares, then we should worry.

1 · Reply

stevelue Aug. 4 at 4:38 PM

$CRDF I also have confidence management is now in active discussions with potential partners from clinical trial collaborations all they way up to an acquisition.

0 · Reply

rag2riches Aug. 4 at 4:24 PM

$CRDF looks like we will be in limbo until year end or 1Q2026 the latest for expected catalysts. We are at the mercy of unexpected positive news. I have confidence management is now in active discussions with potential partners from clinical trial collaborations all they way up to an acquistion.

0 · Reply

JamesST Aug. 4 at 3:37 PM

$CRDF — Patients still on trial close to a -30% response: SOC: -20, -21, -23 Onva 20mg: -27, -27, -27, -28 Onva 30mg: -20, -21, -24, -25, -25, -26 Patients with at least a -50% response already: 17% of control arm 41% of Onva 30mg arm

2 · Reply

PSDL75 Aug. 4 at 3:13 PM

$CRDF Buy signal

1 · Reply

Hurricane76 Aug. 4 at 3:12 PM

$CRDF Bears need this under 2.5 before Aug OPEX... if they c9ver early, this should run

0 · Reply

Cutlass Aug. 4 at 3:10 PM

$CRDF Standing bid at 2.40 GTC - always 🎯

0 · Reply

Get_Out Aug. 4 at 3:06 PM

$CRDF i am a huge holder of shares but I feel screwed after 5 years. Dead money walking. thought this was our time and my average is probably about 4 or so. not putting in more 40K shares or so. fuck an A

1 · Reply

Moominvalley Aug. 4 at 2:56 PM

$CRDF still falling - It’s Not over yet.

0 · Reply

Market Cap	175.63M
Revenue (ttm)	680,000.00
Net Income (ttm)	-45.43M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-6,680.88%
Debt to Equity Ratio	0.00

Volume	3,012,300
Avg Vol	2,006,972
Day's Range	N/A - N/A
Shares Out	66.53M
Stochastic %K	15%
Beta	1.55
Analysts	Strong Sell
Price Target	$12.10